Javier Sanz-rekin lankidetzan egindako argitalpenak (4)

2021

  1. Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure: A Multimodality Study

    JACC: Cardiovascular Imaging, Vol. 14, Núm. 2, pp. 393-407

2020

  1. Correlation between myocardial strain and adverse remodeling in a non-diabetic model of heart failure following empagliflozin therapy

    Expert Review of Cardiovascular Therapy, Vol. 18, Núm. 9, pp. 635-642

2019

  1. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics

    Journal of the American College of Cardiology, Vol. 73, Núm. 15, pp. 1931-1944

2016

  1. Sphingosine-1-phosphate receptor agonist fingolimod increases myocardial salvage and decreases adverse postinfarction left ventricular remodeling in a porcine model of ischemia/reperfusion

    Circulation, Vol. 133, Núm. 10, pp. 954-966